N M Nachreiner1, R G Ghebre, B A Virnig, R Shanley. 1. Division of Environmental Health Sciences, School of Public Health, University of Minnesota, Minneapolis, MN 55455, USA. Joanna.reynolds@lshtm.ac.uk
Abstract
BACKGROUND: Little is known about the balance between work demands and treatment plans for >4.3 million working-age cancer survivors in the USA. AIMS: To describe changes in work status for gynaecological cancer survivors during the first 6 months following diagnosis and their experience with their employers' programmes and policies. METHODS: One hundred and ten gynaecological cancer survivors who were working at the time of their cancer diagnosis completed a survey. Case record reviews documented their clinical characteristics and treatment details. RESULTS: Ninety-five women (86%) had surgery; 81 (74%) received chemotherapy, radiotherapy or both in addition to surgery. Nine per cent of women said that they changed their treatment plan because of their jobs; in contrast, 62% of women said that they changed their work situation to accommodate their treatment plan. Overall, the most common month for women to stop working was Month 1 (41%), to decrease hours was Month 2 (32%) and to increase hours was Month 6 (8%). Twenty-eight per cent of women were aware of employer policies that assisted the return to work process; 70% of women were familiar with the Family and Medical Leave Act (FMLA) and 56% with the Americans with Disabilities Act (ADA). Only 26% completed a formal request for work accommodations. After 6 months, 56 of 83 women (67%) remained working or had returned to work. CONCLUSIONS: Work patterns varied for these gynaecological cancer survivors over the first 6 months following diagnosis. Opportunities exist to improve communication about work and treatment expectations between cancer survivors, occupational health professionals, employers and treating clinicians.
BACKGROUND: Little is known about the balance between work demands and treatment plans for >4.3 million working-age cancer survivors in the USA. AIMS: To describe changes in work status for gynaecological cancer survivors during the first 6 months following diagnosis and their experience with their employers' programmes and policies. METHODS: One hundred and ten gynaecological cancer survivors who were working at the time of their cancer diagnosis completed a survey. Case record reviews documented their clinical characteristics and treatment details. RESULTS: Ninety-five women (86%) had surgery; 81 (74%) received chemotherapy, radiotherapy or both in addition to surgery. Nine per cent of women said that they changed their treatment plan because of their jobs; in contrast, 62% of women said that they changed their work situation to accommodate their treatment plan. Overall, the most common month for women to stop working was Month 1 (41%), to decrease hours was Month 2 (32%) and to increase hours was Month 6 (8%). Twenty-eight per cent of women were aware of employer policies that assisted the return to work process; 70% of women were familiar with the Family and Medical Leave Act (FMLA) and 56% with the Americans with Disabilities Act (ADA). Only 26% completed a formal request for work accommodations. After 6 months, 56 of 83 women (67%) remained working or had returned to work. CONCLUSIONS: Work patterns varied for these gynaecological cancer survivors over the first 6 months following diagnosis. Opportunities exist to improve communication about work and treatment expectations between cancer survivors, occupational health professionals, employers and treating clinicians.
Authors: Nancy M Nachreiner; Rada K Dagher; Patricia M McGovern; Beth A Baker; Bruce H Alexander; Susan Goodwin Gerberich Journal: AAOHN J Date: 2007-07
Authors: R Molina Villaverde; J Feliu Batlle; A Villalba Yllan; A M Jiménez Gordo; A Redondo Sánchez; B San Jose Valiente; M Gonzalez Baron Journal: Occup Med (Lond) Date: 2008-07-30 Impact factor: 1.611
Authors: Mary Stergiou-Kita; Alisa Grigorovich; Victrine Tseung; Elizabeth Milosevic; Debbie Hebert; Stephanie Phan; Jennifer Jones Journal: J Cancer Surviv Date: 2014-07-04 Impact factor: 4.442
Authors: Roni Nitecki; Shuangshuang Fu; Kirsten A Jorgensen; Lauren Gray; Carolyn Lefkowits; Benjamin D Smith; Larissa A Meyer; Alexander Melamed; Sharon H Giordano; Pedro T Ramirez; Jose Alejandro Rauh-Hain Journal: Int J Gynecol Cancer Date: 2021-11-16 Impact factor: 4.661
Authors: Monique C J Leensen; Iris F Groeneveld; Iris van der Heide; Tomas Rejda; Peter L J van Veldhoven; Sietske van Berkel; Aernout Snoek; Wim van Harten; Monique H W Frings-Dresen; Angela G E M de Boer Journal: BMJ Open Date: 2017-06-15 Impact factor: 2.692